S&P 500 Healthcare Sector SEC Filings — November 02, 2026

USA S&P 500 Healthcare

By Gunpowder Editorial ·

15 high priority 2 medium priority 17 total filings analysed

Executive Summary

The 17 filings reveal a healthcare sector bifurcated between resilient recurring-revenue franchises and capital-equipment/litigation-exposed names. IDEXX and Vertex both raised full-year revenue guidance (IDEXX to $4.741-$4.767B; Vertex to $13.15-$13.25B), but both saw margin/expense pressure from acquisitions—IDEXX trimmed operating margin expansion to 50-70 bps from 70-90 bps, and Vertex raised GAAP expense guidance by ~$800M due to Crinetics.

Boston Scientific posted a sharp Q3 deceleration (+1.4% YoY sales) with operating income down 21% on litigation, restructuring, and impairment charges, though nine-month net income rose 27.1% on a lower tax rate. Insider activity was predominantly negative: Gilead's CEO sold $2.78M under a 10b5-1 plan, and two Intuitive Surgical executives sold shares, while Danaher directors received routine phantom-share awards. Board changes at AbbVie and Intuitive Surgical bring payer/digital-health expertise, potentially signaling strategic shifts. Overall, the digest points to slowing growth in capital-intensive medtech, persistent margin headwinds from M&A, and cautious insider sentiment, with opportunities in recurring-revenue diagnostics and select pharma catalysts.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 10-Q · 8-K · Form 4

Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from October 30, 2026.

Investment Signals (12)

  • Q3 revenue grew 9.9% YoY to $1.214B, EPS up 17.9% to $4.01, and nine-month operating cash flow surged 28.7% to $1.063B from $826M; full-year revenue guidance raised to $4.741-$4.767B

  • Q3 revenue rose 12% YoY to $3.44B, driven by CF therapies (+10% U.S., +16% ex-U.S.), and FY2026 revenue guidance raised to $13.15-$13.25B; non-GAAP net income flat at $1.2B despite Crinetics costs

  • Nine-month net income attributable to common stockholders jumped 27.1% YoY to $2.83B, aided by a lower tax expense of $132M vs $463M, and nine-month sales grew 6.7% to $15.784B

  • Seven directors received phantom-share awards at $232.23, totaling ~$248K; while routine, the broad participation may signal alignment with current valuation [NEUTRAL/BULLISH]

  • Appointed Aaron Martin (Humana insurance president, Amazon Clinic founder) to the board effective Jan 1, 2027, bringing payer and digital-health expertise that could support reimbursement and value-based care strategies

  • ▲

    CEO Daniel O'Day sold 15,881 shares at $175.25 (~$2.78M) under a 10b5-1 plan, but retains 551,683 shares; the sale is part of a pre-arranged plan and may not reflect a change in conviction

  • CAG Diagnostics recurring revenue grew 11% organically, with VetLab consumables up 14.3% and reference lab services up 10.0%, demonstrating durable recurring-revenue model

  • New launches contributed to revenue growth, and the company maintained non-GAAP profitability despite a ~$500M hit from Crinetics acquisition-related compensation and transaction expenses

  • Q3 SG&A expenses declined to $1.683B from $1.741B YoY, showing cost discipline even as R&D rose to $520M from $514M [NEUTRAL/BULLISH]

  • Biogen ↓ (NEUTRAL)
    ▲

    Head of Research Jane Grogan exercised 695 RSUs and had 345 shares withheld for taxes at $253.62 (~$87.5K), a routine transaction that increased her holdings to 4,408 shares

  • VP Corporate Controller Fredrik Widman sold 5,448 shares at $436.06 (~$2.38M) under a 10b5-1 plan, reducing holdings to 1,026 shares; the sale represents a significant portion of his stake

  • AbbVie ↓ (NEUTRAL)
    ▲

    Director Jennifer Davis resigned effective Nov 2, 2026, to become CEO of Align Technology; the resignation is not due to any dispute, but the loss of a director could signal a temporary governance gap

Risk Flags (10)

  • Boston Scientific↓ [HIGH RISK]
    ▼

    Q3 2026 net sales grew only 1.4% YoY to $5.138B, a sharp deceleration from nine-month growth of 6.7%; gross profit declined 3.2% and operating income fell 21.0% on $81M litigation charges, $63M restructuring, and $39M impairment

  • IDEXX Laboratories↓ [MEDIUM RISK]
    ▼

    Full-year operating margin guidance lowered to 32.1%-32.3% from 32.3%-32.5%, reducing projected margin expansion to 50-70 bps from 70-90 bps due to acquisition-related impacts; G&A expenses jumped 16.4% YoY, outpacing revenue growth

  • ▼

    FY2026 combined GAAP R&D/AIPR&D/SG&A expense guidance raised to $7.15-$7.2B from $6.3-$6.45B, and non-GAAP expense guidance raised to ~$6.0B from $5.65-$5.75B, signaling cost overruns from Crinetics

  • Gilead Sciences↓ [MEDIUM RISK]
    ▼

    CEO sold $2.78M in shares under a 10b5-1 plan; while pre-arranged, the sale could be perceived negatively by the market, especially if followed by other insiders

  • Intuitive Surgical↓ [MEDIUM RISK]
    ▼

    VP Corporate Controller sold 5,448 shares (~$2.38M), leaving only 1,026 shares; the near-liquidation of his position may raise governance or confidence concerns

  • Boston Scientific↓ [HIGH RISK]
    ▼

    Q3 diluted EPS fell to $0.40 from $0.51 YoY, a 21.6% decline, and net income attributable to common stockholders dropped 22.9% to $582M, highlighting earnings pressure

  • IDEXX Laboratories↓ [MEDIUM RISK]
    ▼

    CAG Diagnostics capital instrument revenue was flat YoY despite over 1,900 inVue Dx placements, and rapid assay revenue rose just 1% due to lower testing volumes, indicating weak equipment demand

  • ▼

    GAAP net income fell sharply to $654M from $1.1B YoY due to ~$500M in Crinetics acquisition-related expenses, and GAAP EPS likely declined significantly

  • AbbVie↓ [LOW RISK]
    ▼

    Director resignation effective Nov 2, 2026, creates a board vacancy; while not due to dispute, the loss of a Class II director could temporarily affect governance and committee work

  • Danaher↓ [LOW RISK]
    ▼

    Phantom-share awards to directors are routine but may dilute shareholders marginally; the awards totaled ~$248K, which is small relative to market cap but worth monitoring for compensation trends

Opportunities (10)

  • IDEXX Laboratories↓ (OPPORTUNITY)
    ◆

    Raised FY2026 revenue guidance to $4.741-$4.767B and EPS to $14.96-$15.16; recurring revenue growth of 11% and strong cash flow ($1.063B operating cash flow) support premium valuation; margin pressure may be temporary

  • ◆

    Revenue guidance raised to $13.15-$13.25B; CF franchise growing double-digits ex-U.S. (+16%), and new launches could drive upside; non-GAAP net income stable at $1.2B despite acquisition costs

  • Boston Scientific↓ (OPPORTUNITY)
    ◆

    Nine-month net income up 27.1% and tax expense sharply lower; if Q3 litigation and restructuring charges are one-time, earnings could rebound in Q4 and 2027

  • Intuitive Surgical↓ (OPPORTUNITY)
    ◆

    Board addition of Aaron Martin brings payer and digital-health expertise, potentially accelerating reimbursement and value-based care initiatives; stock sales by executives under 10b5-1 plans may create buying opportunities if fundamentals remain strong

  • Gilead Sciences↓ (OPPORTUNITY)
    ◆

    CEO sale under 10b5-1 plan may be routine; with 551,683 shares retained, his alignment remains significant; any pullback could be a buying opportunity if pipeline catalysts emerge

  • Danaher↓ (OPPORTUNITY)
    ◆

    Director phantom-share awards at $232.23 may indicate confidence in current valuation; the company's healthcare segment could benefit from post-pandemic normalization

  • Biogen↓ (OPPORTUNITY)
    ◆

    Head of Research exercised RSUs and retained 4,408 shares, signaling confidence; any pipeline progress could drive upside

  • AbbVie↓ (OPPORTUNITY)
    ◆

    Director resignation to lead Align Technology may strengthen ties between the two companies; no operational impact expected, and the board can recruit a replacement with relevant expertise

  • IDEXX Laboratories↓ (OPPORTUNITY)
    ◆

    Strong nine-month operating cash flow of $1.063B vs $826M prior year provides flexibility for acquisitions and buybacks; the $223M business acquisition (goodwill increase) could add growth

  • ◆

    Despite expense guidance increase, revenue guidance raise and non-GAAP profitability suggest the Crinetics deal is strategically sound; long-term pipeline could yield blockbusters

Sector Themes (6)

  • Margin Pressure from M&A
    ◆

    Both IDEXX and Vertex cited acquisition-related costs (IDEXX: $223M business acquisition; Vertex: ~$500M Crinetics expenses) that pressured margins and increased expense guidance, a common theme as healthcare companies deploy cash for growth [IMPLICATION: Expect continued M&A-related volatility in earnings]

  • Recurring Revenue Outperformance
    ◆

    IDEXX's CAG Diagnostics recurring revenue grew 11% organically, while capital equipment was flat; this mirrors a sector-wide preference for recurring-revenue models over capital-intensive medtech [IMPLICATION: Companies with high recurring revenue may command premium valuations]

  • Litigation and Restructuring Headwinds
    ◆

    Boston Scientific's Q3 was hit by $81M litigation, $63M restructuring, and $39M impairment charges, reflecting sector-wide challenges from product liability and portfolio optimization [IMPLICATION: Legal and restructuring costs can create earnings volatility; watch for one-time items]

  • Insider Selling Predominance
    ◆

    Of the insider transactions, Gilead's CEO and two Intuitive Surgical executives sold shares, while only routine awards and RSU exercises were seen on the buy side; this cautious insider sentiment may signal near-term valuation concerns [IMPLICATION: Monitor insider activity for signs of confidence]

  • Board Refreshment with Digital Health Expertise
    ◆

    Intuitive Surgical added a payer/digital-health executive (Aaron Martin), and AbbVie lost a director to a medtech CEO role (Align Technology), indicating healthcare companies are strengthening digital and payer capabilities [IMPLICATION: Strategic focus on value-based care and reimbursement]

  • Guidance Divergence
    ◆

    IDEXX and Vertex raised revenue guidance but lowered margin/expense guidance, while Boston Scientific did not provide guidance in the 10-Q; this divergence highlights varying levels of visibility and cost control [IMPLICATION: Revenue growth may not translate to earnings growth; focus on margin trends]

Watch List (8)

  • Q3 earnings call (date TBD) to discuss litigation charges, restructuring, and whether Q4 guidance will be provided; watch for further details on the $81M litigation and $63M restructuring [DATE: TBD]

  • Q4 2026 earnings call (typically early February 2027) to see if margin guidance is stabilized and whether capital instrument sales recover [DATE: Feb 2027]

  • Q4 2026 earnings call (typically early February 2027) to assess Crinetics integration and expense trajectory; watch for 2027 guidance [DATE: Feb 2027]

  • Monitor insider transactions for additional sales by CEO or other executives; the 10b5-1 plan may have more sales scheduled [DATE: Ongoing]

  • Board appointment of Aaron Martin effective Jan 1, 2027; watch for strategic announcements regarding payer partnerships or digital health initiatives [DATE: Jan 1, 2027]

  • 👁

    Board vacancy following Jennifer Davis's resignation; watch for a replacement director with relevant expertise and any strategic implications [DATE: TBD]

  • 👁

    Phantom-share awards to directors may be followed by other compensation changes; monitor for any shifts in capital allocation [DATE: Ongoing]

  • 👁

    Head of Research Jane Grogan's RSU exercise and retention of shares; watch for pipeline updates or additional insider activity [DATE: Ongoing]

Filing Analyses (17)
IDEXX LABORATORIES INC /DE 10-Q positive materiality 8/10

02-11-2026

IDEXX reported Q3 2026 revenue of $1,214,237 thousand, up 9.9% YoY from $1,105,239 thousand, with net income rising 15.5% to $317,145 thousand and diluted EPS up 17.9% to $4.01. CAG segment revenue grew 10.2% to $1,115,968 thousand, driven by IDEXX VetLab consumables (+14.3%) and reference lab services (+10.0%), while CAG Diagnostics capital instruments were flat at $51,492 thousand. However, gross margin compressed to 62.9% from 61.8% prior year on higher cost of service revenue, and general and administrative expenses jumped 16.4% YoY, outpacing revenue growth.

  • · Gross margin improved to 62.9% from 61.8% YoY despite higher cost of service revenue
  • · Nine-month operating cash flow rose to $1,063,127 thousand from $826,045 thousand
  • · Goodwill increased to $640,506 thousand from $414,004 thousand at Dec 31, 2025, reflecting a $223,430 thousand business acquisition
  • · Company repurchased $810,014 thousand of stock over nine months, reducing shares outstanding to 78,790 thousand
  • · CAG Diagnostics capital instruments revenue was flat YoY at $51,492 thousand
  • · LPD segment grew only 2.6% YoY, the slowest of the reporting segments
  • · Foreign currency translation swung to a $13,928 thousand loss from a $58,434 thousand gain in the prior-year period
  • · Diluted weighted average shares fell to 79,049 thousand from 80,675 thousand
IDEXX LABORATORIES INC /DE 8-K mixed materiality 8/10

02-11-2026

IDEXX reported Q3 2026 revenue of $1,214 million, up 10% as reported and organic, with CAG Diagnostics recurring revenue up 11% and EPS of $4.01 (+18% reported, +22% comparable). However, growth was uneven: rapid assay revenue rose just 1% and CAG Diagnostics capital instrument revenue was flat, while operating margin guidance was lowered to 32.1%-32.3% (from 32.3%-32.5%) due to acquisition-related impacts. The company raised full-year revenue guidance to $4,741-$4,767 million and EPS to $14.96-$15.16, but trimmed projected operating margin expansion to 50-70 bps from 70-90 bps.

  • · Rapid assay products revenue increased only 1% as reported and organic, with lower testing volumes offset by net price benefits.
  • · CAG Diagnostics capital instrument revenues were flat as reported and organic despite over 1,900 IDEXX inVue Dx placements.
  • · Full-year reported operating margin outlook was lowered to 32.1%-32.3% from 32.3%-32.5%, reducing projected margin expansion to 50-70 bps from 70-90 bps.
  • · 2026 EPS guidance raised to $14.96-$15.16, a $0.25 increase versus prior midpoint, implying 14%-16% reported growth.
  • · Q3 EPS included a $0.03 non-operating equity investment gain, $0.01 tax benefit from share-based compensation, and $0.04 FX benefit.
  • · Estimated 2026 FX impacts: ~0.7% revenue growth, ~30 bps operating margin, ~$0.25 EPS.
  • · Projected 2026 effective tax rate lowered to ~20.5% from ~21.1%; net interest expense reduced to ~$32M from ~$35M.
  • · Capital expenditures guidance reduced to ~$160M from ~$180M.
  • · Operating cash flow projected at 110%-120% of net income; free cash flow at 95%-100%.
  • · Investor and Analyst Session at VMX in Orlando on January 18, 2027 at 1:00 p.m. ET to highlight IDEXX MultiCue Dx.
AbbVie Inc. 8-K neutral materiality 3/10

02-11-2026

AbbVie Inc. disclosed in an 8-K (Item 5.02) that Class II director Jennifer L. Davis resigned from the Board effective November 2, 2026, following her appointment as Chief Executive Officer of Align Technology, Inc. The company stated the resignation is not the result of any dispute or disagreement with AbbVie on operations, policies or practices. No financial terms, compensatory arrangements, or replacement director were disclosed.

  • · Resignation notice given October 28, 2026; effective date November 2, 2026
  • · Davis is a Class II director of AbbVie
  • · Reason cited: her recent appointment as Chief Executive Officer at Align Technology, Inc.
  • · AbbVie explicitly stated the resignation is not due to any dispute or disagreement on operations, policies or practices
  • · Filing signed by Perry C. Siatis, Executive Vice President, General Counsel and Secretary, dated November 2, 2026
  • · No successor director, committee reassignment, or compensatory arrangement was disclosed
VERTEX PHARMACEUTICALS INC / MA 8-K mixed materiality 8/10

02-11-2026

Vertex reported Q3 2026 total revenue of $3.44 billion, up 12% YoY, driven by CF therapies (+10% U.S. to $2.17 billion, +16% ex-U.S. to $1.27 billion) and new launches. However, GAAP net income fell sharply to $654 million from $1.1 billion YoY due to ~$500 million in Crinetics acquisition-related compensation and transaction expenses, while non-GAAP net income was flat at $1.2 billion. Vertex raised FY2026 revenue guidance to $13.15-$13.25 billion but also increased combined GAAP R&D/AIPR&D/SG&A expense guidance to $7.15-$7.2 billion from $6.3-$6.45 billion.

  • · FY2026 revenue guidance raised to $13.15-$13.25 billion from prior $13.1-$13.2 billion
  • · FY2026 combined GAAP R&D/AIPR&D/SG&A expense guidance raised to $7.15-$7.2 billion from $6.3-$6.45 billion
  • · FY2026 non-GAAP expense guidance raised to ~$6.0 billion from $5.65-$5.75 billion
  • · Cash declined to $9.8 billion from $12.3 billion at Dec 31, 2025
  • · Povetacicept PDUFA target action date November 30, 2026
  • · Crinetics acquisition closed September 1, 2026
  • · PALSONIFY approved in EU April 2026; European launches expected H2 2027
  • · JOURNAVX became most prescribed branded oral pain medicine in U.S. as of August 2026
  • · Suzetrigine DPN Phase 3 enrollment on track to complete by end of 2026, results mid-2027
  • · Inaxaplin AMPLIFIED Phase 2b showed UACR -42.7% and UPCR -44.7% in modest proteinuria cohort
  • · FY2026 revenue guidance includes ~150 bps FX benefit YoY
INTUITIVE SURGICAL INC 8-K neutral materiality 4/10

02-11-2026

Intuitive Surgical appointed Aaron Martin, currently President of Insurance at Humana, to its board of directors effective January 1, 2027, expanding the board from 10 to 11 members. Martin brings payer, digital health, and venture experience from Humana, Amazon (where he launched Amazon Clinic), and Providence St. Joseph Health, but the appointment is subject to his continued willingness and ability to serve. No financial results or guidance were disclosed in this filing.

  • · Appointment effective January 1, 2027, subject to Martin's continued willingness and ability to serve
  • · Martin reports to Humana's CEO and serves on the Humana Enterprise Leadership Team
  • · Martin held board roles at Kyruus, Wildflower Health, Xealth, DexCare, AVIA, and Presbyterian Health System
  • · Martin holds a BA from Austin College and an MBA from the Wharton School
DANAHER CORP /DE/ 4 neutral materiality 3/10

02-11-2026

Director Zerhouni Elias A. was awarded 199.085 Phantom shares at $232.23 (~$46.2K).

  • · Director Zerhouni Elias A. was awarded 199.085 Phantom shares at $232.23 (~$46.2K)
DANAHER CORP /DE/ 4 neutral materiality 3/10

02-11-2026

Director Stevens Raymond C was awarded 152.741 Phantom shares at $232.23 (~$35.5K).

  • · Director Stevens Raymond C was awarded 152.741 Phantom shares at $232.23 (~$35.5K)
DANAHER CORP /DE/ 4 neutral materiality 4/10

02-11-2026

Director List Teri was awarded 13.222 Phantom shares at $232.23 (~$3.07K).

  • · Director List Teri was awarded 13.222 Phantom shares at $232.23 (~$3.07K)
DANAHER CORP /DE/ 4 neutral materiality 3/10

02-11-2026

Director Dewan Feroz was awarded 144.029 Phantom shares at $232.23 (~$33.4K).

  • · Director Dewan Feroz was awarded 144.029 Phantom shares at $232.23 (~$33.4K)
DANAHER CORP /DE/ 4 neutral materiality 3/10

02-11-2026

Director FILLER LINDA was awarded 15.424 Phantom shares at $232.23 (~$3.58K).

  • · Director FILLER LINDA was awarded 15.424 Phantom shares at $232.23 (~$3.58K)
DANAHER CORP /DE/ 4 neutral materiality 3/10

02-11-2026

Director Sanders A Shane was awarded 177.692 Phantom shares at $232.23 (~$41.3K).

  • · Director Sanders A Shane was awarded 177.692 Phantom shares at $232.23 (~$41.3K)
DANAHER CORP /DE/ 4 neutral materiality 3/10

02-11-2026

Director SPOON ALAN G was awarded 193.416 Phantom shares at $232.23 (~$44.9K).

  • · Director SPOON ALAN G was awarded 193.416 Phantom shares at $232.23 (~$44.9K)
BOSTON SCIENTIFIC CORP 10-Q mixed materiality 8/10

02-11-2026

Boston Scientific reported Q3 2026 net sales of $5,138M, up just 1.4% YoY from $5,065M, while gross profit declined 3.2% to $3,428M as cost of products sold jumped 12.3% to $1,710M. Operating income fell 21.0% to $828M and net income attributable to common stockholders dropped 22.9% to $582M (diluted EPS $0.40 vs $0.51), pressured by higher costs, $81M litigation-related net charges, $63M restructuring charges, and $39M intangible impairment. However, nine-month results improved: net sales rose 6.7% to $15,784M and net income attributable to common stockholders grew 27.1% to $2,830M, aided by a lower tax expense of $132M vs $463M.

  • · Q3 2026 SG&A expenses declined to $1,683M from $1,741M YoY, while R&D rose to $520M from $514M.
  • · Nine-month 2026 gross profit rose to $10,890M from $10,175M, but operating expenses increased to $7,783M from $7,387M.
  • · Nine-month 2026 tax expense fell sharply to $132M from $463M, boosting net income.
  • · Cash and cash equivalents fell to $609M from $1,965M at year-end 2025, while current debt obligations rose to $1,044M from $299M.
  • · Treasury stock increased to $4,318M from $2,251M, reflecting $2,000M of share repurchases in 2026.
  • · Nine-month 2026 investing outflows were $2,984M vs $2,128M, driven by $1,801M of technology investments/acquisitions.
  • · Inventories rose to $3,317M from $2,943M and goodwill increased to $18,736M from $18,282M.
  • · Other investments jumped to $2,292M from $681M.
BIOGEN INC. 4 neutral materiality 4/10

02-11-2026

Head of Research Grogan Jane had withheld for taxes 345 Common Stock at $253.62 (~$87.5K). Grogan Jane holds 4,408 shares after the transaction.

  • · Head of Research Grogan Jane exercised/converted 695 Common Stock
  • · Head of Research Grogan Jane had withheld for taxes 345 Common Stock at $253.62 (~$87.5K)
  • · Head of Research Grogan Jane exercised/converted 695 Restricted Stock Unit
GILEAD SCIENCES, INC. 4 negative materiality 6/10

02-11-2026

Chairman & CEO O'Day Daniel Patrick sold 15,881 Common Stock at $175.25 (~$2.78M). 8 transactions reported in total. O'Day Daniel Patrick holds 551,683 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · Chairman & CEO O'Day Daniel Patrick exercised/converted 15,881 Common Stock at $72.34 (~$1.15M)
  • · Chairman & CEO O'Day Daniel Patrick sold 15,881 Common Stock at $175.25 (~$2.78M)
  • · Chairman & CEO O'Day Daniel Patrick sold 1,600 Common Stock at $167.40 (~$268K)
  • · Chairman & CEO O'Day Daniel Patrick sold 1,700 Common Stock at $168.10 (~$286K)
  • · Chairman & CEO O'Day Daniel Patrick sold 1,904 Common Stock at $169.27 (~$322K)
  • · Chairman & CEO O'Day Daniel Patrick sold 7,796 Common Stock at $170.35 (~$1.33M)
  • · Chairman & CEO O'Day Daniel Patrick sold 2,000 Common Stock at $171.06 (~$342K)
  • · Chairman & CEO O'Day Daniel Patrick exercised/converted 15,881 Non-qualified Stock Option (Right to Buy)
INTUITIVE SURGICAL INC 4 negative materiality 7/10

02-11-2026

VP Corporate Controller Widman Fredrik sold 5,448 Common Stock at $436.06 (~$2.38M). 29 transactions reported in total. Widman Fredrik holds 1,026 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · VP Corporate Controller Widman Fredrik exercised/converted 546 Common Stock at $79.64 (~$43.5K)
  • · VP Corporate Controller Widman Fredrik exercised/converted 312 Common Stock at $208.90 (~$65.2K)
  • · VP Corporate Controller Widman Fredrik exercised/converted 325 Common Stock at $139.52 (~$45.3K)
  • · VP Corporate Controller Widman Fredrik exercised/converted 307 Common Stock at $304.67 (~$93.5K)
  • · VP Corporate Controller Widman Fredrik exercised/converted 307 Common Stock at $229.39 (~$70.4K)
  • · VP Corporate Controller Widman Fredrik exercised/converted 312 Common Stock at $290.33 (~$90.6K)
  • · VP Corporate Controller Widman Fredrik exercised/converted 406 Common Stock at $347.42 (~$141K)
  • · VP Corporate Controller Widman Fredrik exercised/converted 406 Common Stock at $245.60 (~$99.7K)
INTUITIVE SURGICAL INC 4 negative materiality 3/10

02-11-2026

EVP & Chief Mfg and Supply Cha Brosius Mark sold 63 Common Stock at $453.60 (~$28.6K). Brosius Mark holds 457 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · EVP & Chief Mfg and Supply Cha Brosius Mark sold 61 Common Stock at $447.85 (~$27.3K)
  • · EVP & Chief Mfg and Supply Cha Brosius Mark sold 63 Common Stock at $453.60 (~$28.6K)

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 17 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: S&P 500 Healthcare Sector SEC Filings

🇺🇸 More from United States

View all →